LLY
Eli Lilly and Co
NEW YORK STOCK EXCHANGE, INC.· Pharmaceuticals· US· IPO 1970-07-09
$1160.08
+0.08 (+0.01%)
last quote
Want the full multi-source brief on LLY?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$1160.08
High
$1187.83
Low
$1158.00
Previous close
$1160.00
Fundamentals
Market cap
$1.15T
P/E (TTM)
43.17x
P/S (TTM)
14.47x
P/B
38.29x
Gross margin
83.40%
Operating margin
42.22%
Net margin
33.53%
Rev growth (YoY)
49.58%
EPS growth (YoY)
94.62%
ROE
92.58%
52W high
$1292.65
52W low
$712.05
Beta
0.43x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-10-29in 55 days
Q3 2026EPS est $9.88Rev est $22396.3M
Recent SEC filings
CIK 59478filing-language history →
Recent news
2026-08-27 → 2026-09-03
Yahoo · 8h
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices. The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL,...
Yahoo · 9h
Eli Lilly Just Announced a Major Acquisition. Here's What It Means.
The drug giant added to its immunotherapy portfolio.
Yahoo · 11h
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.
Yahoo · 12h
How Did Merck Stock Beat The Market With Slowing Sales?
Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.
Yahoo · 13h
Lilly’s Record Stock Price Is Hiding an Even Bigger Opportunity
Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why the real opportunity may still be ahead.
Yahoo · 15h
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.
Yahoo · 15h
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.
Yahoo · 17h
Peptide innovator says the drug class is due for a rethink
Karsten Eastman, CEO of Sethera Therapeutics, discusses developments in peptides from cutting-edge innovation to mass consumption.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial